RU2011125776A - Композиции и способы лечения гиперпигментации - Google Patents

Композиции и способы лечения гиперпигментации Download PDF

Info

Publication number
RU2011125776A
RU2011125776A RU2011125776/15A RU2011125776A RU2011125776A RU 2011125776 A RU2011125776 A RU 2011125776A RU 2011125776/15 A RU2011125776/15 A RU 2011125776/15A RU 2011125776 A RU2011125776 A RU 2011125776A RU 2011125776 A RU2011125776 A RU 2011125776A
Authority
RU
Russia
Prior art keywords
gly
acid
skin
topical composition
positively charged
Prior art date
Application number
RU2011125776/15A
Other languages
English (en)
Russian (ru)
Inventor
Джекоб М. ВОГ
Original Assignee
Реванс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Реванс Терапьютикс, Инк. filed Critical Реванс Терапьютикс, Инк.
Publication of RU2011125776A publication Critical patent/RU2011125776A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2011125776/15A 2008-12-31 2009-12-28 Композиции и способы лечения гиперпигментации RU2011125776A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14209408P 2008-12-31 2008-12-31
US61/142,094 2008-12-31
PCT/US2009/069578 WO2010078244A1 (en) 2008-12-31 2009-12-28 Compositions and methods for treating hyperpigmentation

Publications (1)

Publication Number Publication Date
RU2011125776A true RU2011125776A (ru) 2013-02-10

Family

ID=42285228

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011125776/15A RU2011125776A (ru) 2008-12-31 2009-12-28 Композиции и способы лечения гиперпигментации

Country Status (8)

Country Link
US (2) US20100166689A1 (enExample)
EP (1) EP2379177A1 (enExample)
JP (1) JP5836128B2 (enExample)
KR (1) KR20110112381A (enExample)
CN (1) CN102292126B (enExample)
RU (1) RU2011125776A (enExample)
SG (1) SG172811A1 (enExample)
WO (1) WO2010078244A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2778786C2 (ru) * 2017-07-24 2022-08-24 Олипасс Корпорейшн Антисмысловые олигонуклеотиды тирозиназы
US11739124B2 (en) 2018-08-14 2023-08-29 Olipass Corporation Acetyl-CoA carbosylase2 antisense oligonucleotides

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2006094263A2 (en) * 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
CN104857514B (zh) * 2015-05-15 2018-01-19 东华大学 一种胰岛素脂质体透皮促进剂及其制备方法
KR102607534B1 (ko) * 2015-12-28 2023-11-29 오비다트 주식회사 TATdMt 펩타이드를 포함하는 미백 조성물
KR102206808B1 (ko) * 2019-09-05 2021-01-26 주식회사 에스스킨 신규한 세포-투과 펩타이드 및 이를 포함하는 피부 개선용 조성물
KR20220070246A (ko) 2019-09-23 2022-05-30 디디에스 리서치 인크. 침투 증진제를 갖는 지질 소포 조성물
MX2023011157A (es) 2021-03-24 2024-01-25 Glo Pharma Inc Peptidos y metodos para reducir la pigmentacion de la piel.
WO2024048890A1 (ko) * 2022-08-31 2024-03-07 주식회사 레메디 피부 미백 활성을 가지는 펩타이드를 포함하는 조성물
AU2024349812A1 (en) * 2023-09-25 2026-04-09 Revance Therapeutics, Inc. Methods for determining influence of carrier peptide on the binding of a therapeutic protein to a cell membrane

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6483010A (en) * 1987-09-25 1989-03-28 Sansho Seiyaku Kk Melanization inhibitory drug for external use
US6544548B1 (en) * 1999-09-13 2003-04-08 Keraplast Technologies, Ltd. Keratin-based powders and hydrogel for pharmaceutical applications
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20070154437A1 (en) * 2002-09-03 2007-07-05 Pingfan Rao Peptide-tagged proteins and methods of making and using thereof
US20040043463A1 (en) * 2002-09-03 2004-03-04 Pingfan Rao Peptide-tagged proteins and compositions for regulating features of the skin or hair; methods of making, and methods of using thereof
CA2558408C (en) * 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2778786C2 (ru) * 2017-07-24 2022-08-24 Олипасс Корпорейшн Антисмысловые олигонуклеотиды тирозиназы
RU2778786C9 (ru) * 2017-07-24 2022-10-14 Олипасс Корпорейшн Антисмысловые олигонуклеотиды тирозиназы
US11739124B2 (en) 2018-08-14 2023-08-29 Olipass Corporation Acetyl-CoA carbosylase2 antisense oligonucleotides

Also Published As

Publication number Publication date
US20100166689A1 (en) 2010-07-01
CN102292126B (zh) 2016-10-12
JP2012514004A (ja) 2012-06-21
WO2010078244A1 (en) 2010-07-08
SG172811A1 (en) 2011-08-29
KR20110112381A (ko) 2011-10-12
CN102292126A (zh) 2011-12-21
EP2379177A1 (en) 2011-10-26
JP5836128B2 (ja) 2015-12-24
US20120014894A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
MY177065A (en) 4-1bb binding molecules
BR112015023001A2 (pt) composição de salto de exon para tratamento de distrofia muscular
EA201491265A1 (ru) Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
EA201491260A1 (ru) Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
EA201491264A1 (ru) Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
MX2010008096A (es) Anticuerpos de ferroportina y metodos de uso.
MX2012012119A (es) Produccion de proteinas heteromultimericas.
EP4616914A3 (en) Polypeptides binding to human complement c5
BRPI0508931A (pt) ácido nucleico isolado, composição farmacêutica e usos de uma quantidade eficaz de um primeiro ligante de ácido nucleico
WO2011103016A3 (en) Compositions and methods for inhibiting ezh2
EP2568956A4 (en) COMPOSITIONS WITH A DNA REPAIR CYM AND AN ANAGEISSUS EXTRACT
WO2012112690A3 (en) Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
NZ593249A (en) Optically-based stimulation of target cells and modifications thereto
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
NZ708528A (en) Anti-ceacam5 antibodies and uses thereof
UA89957C2 (ru) Химерные аденовирусы для применения для лечения злокачественного новообразования
RU2015119517A (ru) Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
BR112012027053A2 (pt) formulação precursora de hidrogel e processo de produção do mesmo
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
TN2011000524A1 (en) Antibodies specific to cadherin -17
BRPI0920655A2 (pt) conjugados e hpma-docetaxel ou gencitabina e usos dos mesmos
TN2009000194A1 (en) Novel antiproliferation antibodies
EA201491268A1 (ru) Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами по связыванию
EA201491259A1 (ru) Соединения и композиции для ингибирования взаимодействия bcl2 с партнерами связывания
BR112012012911A2 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo, in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140110